Tag: Diabetes: Drugs
Metformin May Cut Mortality Risk in Post-Pancreatitis Diabetes
Survival benefit not seen with ever use of metformin for pancreatic cancer-related diabetes
Second-Line Antidiabetic Meds May Impact Cardiovascular Risk
Cardiovascular risk increased with sulfonylureas and basal insulin versus newer classes of ADM
DPP-4I Not Tied to Increased Risk of Acute Pancreatitis in Seniors
Among adults with heart disease, risk increased with DPP-4I versus thiazolidinedione not sulfonylureas
Exposure to Metformin In Utero Ups Risk of Being Overweight
Findings among children of women with polycystic ovary syndrome on metformin during pregnancy
No Link Found for Metformin or Statins and Ovarian Cancer
Findings based on a Finnish study involving a national cohort of women with type 2 diabetes
Bariatric Surgery Linked to Discontinuing Diabetes Meds
Six-year antidiabetes treatment initiation rate also much lower after bariatric surgery
Dasiglucagon Well Tolerated for Severe Hypoglycemia
Early pharmacodynamic response similar to that of GlucaGen, with longer lasting effects plasma glucose
Adherence to T2DM Treatment Varies Across Medication Classes
Adherence better for sulfonylureas and thiazolidinediones compared with metformin
Fat Intake Influences HbA1c-Lowering Effect in DPP4i Therapy
Saturated fat intake is significantly correlated with change in HbA1c during DPP4i monotherapy
First-Line Metformin Use for DM Up; Sulfonylurea Use Down
But sulfonylureas still most common drugs initiated as second-line treatment
